Gayatri BioOrga.

Who are the top shareholders of the Gayatri BioOrga.?

The top shareholders of Gayatri BioOrga include promoter Sandeep Kumar Reddy Tikkavarapu with 21.59% and public shareholder Fursa Mauritius Spv 1 with 23.48%. Individual investors hold 53.01% of shares, while mutual funds and foreign institutional investors hold minor stakes.

The top shareholders of Gayatri BioOrga include Sandeep Kumar Reddy Tikkavarapu, who is the promoter with the highest holding at 21.59%. Additionally, the highest public shareholder is Fursa Mauritius Spv 1, holding 23.48%. Individual investors collectively hold 53.01% of the shares. The company also has some mutual fund representation, with three schemes holding 0.65%, and one foreign institutional investor holding 0.01%. There are no pledged promoter holdings reported.

What does Gayatri BioOrga. do?

Gayatri BioOrganics Ltd is a micro-cap company specializing in the manufacture of starch, modified starches, liquid glucose, and sorbitol. Incorporated in 1991, it reported a net profit of 0 Cr for March 2025, with a market cap of Rs 59 Cr.

Overview: <BR>Gayatri BioOrganics Ltd is a leading manufacturer of starch, modified starches, liquid glucose, sorbitol, and allied products in the commodity chemicals industry, categorized as a micro-cap company.<BR><BR>History: <BR>Incorporated on December 02, 1991, Gayatri BioOrganics Ltd was formerly known as Gayatri Starchkem Ltd. The latest quarterly results reported are for March 2025, showing a net profit of 0 Cr.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 59 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.03 <BR>Return on Equity: 2.84% <BR>Price-to-Book: -1.63<BR><BR>Contact Details: <BR>Address: 6-3-1090 B-Block 3rd Floor, TSRTowers, Rajbhavan Rd, Somajiguda, Hyderabad, Telangana: 500082 <BR>Tel: 91-40-66100111 <BR>Fax: 91-40-66100333 <BR>Email: info@gayatribioorganics.com <BR>Website: http://www.gayatribioorganics.com

Has Gayatri BioOrga. declared dividend?

No Dividend History Available

Who are the peers of the Gayatri BioOrga.?

Peers of Gayatri BioOrga. include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Genus Prime, Camex, Haryana Leather, and Ritesh Intl. In terms of management risk, GHCL has excellent management, while Chemplast Sanmar and others are rated good; India Glycols has the highest 1-year return at 150.85%, and Gayatri BioOrga. has a return of 27.16%.

Peers: The peers of Gayatri BioOrga. are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Genus Prime, Camex, Haryana Leather, and Ritesh Intl.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar and the rest. Average management risk is present at Tata Chemicals, India Glycols, and Haryana Leather, while Below Average management risk is noted at Fischer Medical and Camex. The remaining peers, Genus Prime and Gayatri BioOrga., do not qualify for management risk assessment. Growth ratings show that Good growth is seen at Ritesh Intl., while Below Average growth is noted at Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Haryana Leather, and Camex, with the rest not qualifying. Capital Structure is Excellent at GHCL, Good at Fischer Medical and Haryana Leather, Average at Tata Chemicals and Ritesh Intl., and Below Average at Chemplast Sanmar, India Glycols, and Camex, with the remaining peers not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is India Glycols at 150.85%, while the lowest is Chemplast Sanmar at -12.64%. Gayatri BioOrga.'s 1-year return of 27.16% is higher than Chemplast Sanmar's but lower than India Glycols'. Additionally, Camex and Haryana Leather have negative six-month returns.

Is Gayatri BioOrga. overvalued or undervalued?

As of April 25, 2023, Gayatri BioOrga is classified as risky and overvalued, with negative key ratios indicating financial struggles, despite a 34.16% return over the past year, outperforming the Sensex's 7.57%.

As of 25 April 2023, the valuation grade for Gayatri BioOrga. has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -58.43, an EV to EBIT of -95.74, and a ROCE of -38.46%. <BR><BR>In comparison to peers, Solar Industries is classified as very expensive with a PE ratio of 123.77, while Godrej Industries is attractive with a PE ratio of 46.63. The significant negative ratios for Gayatri BioOrga. suggest that the company is struggling financially, which is reflected in its poor performance relative to the Sensex, although it has outperformed the index over the past year with a return of 34.16% compared to the Sensex's 7.57%.

What is the technical trend for Gayatri BioOrga.?

As of May 14, 2025, Gayatri BioOrga's technical trend is bullish, supported by strong daily and weekly indicators, despite mild bullishness in the monthly MACD and KST.

As of 14 May 2025, the technical trend for Gayatri BioOrga has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate a bullish stance. The weekly KST is bullish, further reinforcing the upward momentum. Although the monthly MACD and KST are only mildly bullish, the overall strength of the trend is supported by the daily indicators. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting a potential for continued upward movement. The Dow Theory shows a mildly bullish trend on the weekly chart, but no trend on the monthly. Overall, the current technical stance is bullish with strong indicators from the daily and weekly time frames.

Who are in the management team of Gayatri BioOrga.?

As of March 2022, the management team of Gayatri BioOrga includes T V Sandeep Kumar Reddy (Executive Chairman), K. Sridhar Reddy (Whole-time Director), Meenakshi Ramchand Sachdeva (Director), and several independent directors: Murali Vittala, P V Narayana Rao, and Ch Ramachandra Seshaprasad, along with Aamir Tak as Company Secretary & Compliance Officer.

As of March 2022, the management team of Gayatri BioOrga includes the following individuals:<BR><BR>1. T V Sandeep Kumar Reddy - Executive Chairman<BR>2. Murali Vittala - Independent Director<BR>3. P V Narayana Rao - Independent Director<BR>4. Ch Ramachandra Seshaprasad - Independent Director<BR>5. K. Sridhar Reddy - Whole-time Director<BR>6. Meenakshi Ramchand Sachdeva - Director<BR>7. Aamir Tak - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive and independent directors, along with a compliance officer.

How big is Gayatri BioOrga.?

As of 24th July, Gayatri BioOrganics Ltd has a market capitalization of 69.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 0.72 Cr. The latest balance sheet shows Shareholder's Funds at a loss of 35.17 Cr and Total Assets valued at 1.58 Cr.

As of 24th July, Gayatri BioOrganics Ltd has a market capitalization of 69.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit loss of 0.72 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds at a loss of 35.17 Cr and Total Assets valued at 1.58 Cr.

How has been the historical performance of Gayatri BioOrga.?

Gayatri BioOrga has faced significant financial challenges, reporting minimal revenue and consistent losses, with net sales dropping to zero in 2024 and 2025, and negative reserves of -114.68 Cr by March 2025. The company has not generated any cash flow from operations since March 2020.

Answer:<BR>The historical performance of Gayatri BioOrga shows a challenging trend with minimal revenue generation and consistent losses over the years.<BR><BR>Breakdown:<BR>Gayatri BioOrga reported net sales of 1.67 Cr in March 2023, but this figure dropped to 0.00 Cr in both March 2024 and March 2025, indicating a complete halt in revenue generation. The total operating income mirrored this trend, remaining at 0.00 Cr for the last two years after a peak in March 2023. The company's expenditures, excluding depreciation, were 2.44 Cr in March 2023, decreasing to 0.45 Cr by March 2025, yet the operating profit continued to be negative, with losses of -0.45 Cr in March 2025 compared to -0.77 Cr in March 2023. The profit before tax also remained negative, with a loss of -0.73 Cr in March 2025. The company's reserves have been in a negative state, reaching -114.68 Cr in March 2025, while shareholder's funds also reflected a negative balance of -35.89 Cr. Cash flow from operating activities has been non-existent since March 2020, with no cash inflow or outflow reported in the last three years. Overall, Gayatri BioOrga's financial performance indicates significant operational challenges and a lack of profitability.

When is the next results date for Gayatri BioOrganics Ltd?

The next results date for Gayatri BioOrganics Ltd is 10 February 2026.

The next results date for Gayatri BioOrganics Ltd is scheduled for 10 February 2026.

Are Gayatri BioOrganics Ltd latest results good or bad?

Gayatri BioOrganics Ltd's latest results are concerning, showing zero revenue for seven quarters and a net loss of ₹0.22 crores in Q3 FY26, indicating severe financial distress and negative shareholder equity. Investors should exercise caution due to the company's critical financial health and lack of a clear recovery path.

The latest results for Gayatri BioOrganics Ltd are concerning and indicate a very poor financial situation. The company has reported zero revenue for seven consecutive quarters, which highlights a complete operational shutdown. In the most recent quarter (Q3 FY26), Gayatri BioOrganics incurred a net loss of ₹0.22 crores, continuing a trend of mounting losses and negative shareholder equity amounting to ₹35.89 crores.<BR><BR>The company's book value is negative at ₹4.56 per share, reflecting severe capital erosion. With no sales and ongoing operational paralysis, the financial health of the company is critical. Additionally, the promoter's stake has significantly decreased, which raises further concerns about confidence in the company's future.<BR><BR>Overall, the financial results suggest that Gayatri BioOrganics is in a state of distress, making the outlook quite bleak. Investors should approach this situation with caution, as there appears to be no clear path to recovery or profitability.

Should I buy, sell or hold Gayatri BioOrganics Ltd?

Why is Gayatri BioOrganics Ltd falling/rising?

As of 30-Mar, Gayatri BioOrganics Ltd's stock price is rising to 13.82 after a trend reversal, but it has faced significant volatility with a year-to-date drop of 21.66%. Despite this, it has generated a remarkable return of 96.59% over the past year, outperforming the benchmark index.

As of 30-Mar, Gayatri BioOrganics Ltd's stock price is rising, currently at 13.82, reflecting a change of 0.13 (0.95%) upward. This increase comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, it has outperformed its sector by 3.21% today, indicating a positive movement relative to its peers.<BR><BR>Despite the recent rise, the stock has experienced significant volatility, with a 1-week decline of 11.35% and a year-to-date drop of 21.66%. However, over the past year, it has shown remarkable performance, generating a return of 96.59%, which is substantially higher than the negative return of -7.06% from the benchmark index, Sensex.<BR><BR>The stock's current price is above the 200-day moving average, although it remains below the shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), suggesting mixed signals regarding its short-term momentum. Furthermore, the delivery volume has seen a drastic decline of 83.77% compared to the 5-day average, indicating falling investor participation, which could pose a risk to sustained price increases.<BR><BR>In summary, while Gayatri BioOrganics Ltd is currently experiencing a rise in stock price, it is important to consider the broader context of its recent performance, volatility, and investor engagement.

Which are the latest news on Gayatri BioOrga.?